Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2

A lead compound obtained from a high volume human non-pancreatic secretory phospholipase A2 (hnps-PLA2) screen has been developed into a potent inhibitor using detailed structural knowledge of inhibitor binding to the enzyme active site. Four crystal structures of hnps-PLA2 complexed with a series of increasingly potent indole inhibitors were determined and used as the structural basis for both understanding this binding and providing valuable insights for further development. The application of structure-based drug design has made possible improvements in the binding of this screening lead to the enzyme by nearly three orders of magnitude. Furthermore, the optimized structure (LY311727) displayed 1,500-fold selectivity when assayed against porcine pancreatic s-PLA2.

[1]  R. Kramer,et al.  Structure and properties of a human non-pancreatic phospholipase A2. , 1989, The Journal of biological chemistry.

[2]  C. Benjamin,et al.  Are Events After Endotoxemia Related to Circulating Phospholipase A2 ? , 1994, Annals of surgery.

[3]  P. Elsbach,et al.  Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[4]  I. Kuntz,et al.  Structure-based discovery of inhibitors of thymidylate synthase. , 1993, Science.

[5]  Y. Hannun,et al.  Role of phospholipases in generating lipid second messengers in signal transduction 1 , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  P. Sigler,et al.  Crystal structure of cobra-venom phospholipase A2 in a complex with a transition-state analogue. , 1990, Science.

[7]  S E Ealick,et al.  Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Dennis.  Diversity of group types, regulation, and function of phospholipase A2. , 1994, The Journal of biological chemistry.

[9]  J. Browning,et al.  Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. , 1993, Journal of lipid mediators.

[10]  D. Norbeck,et al.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.

[11]  PatrickY.-S. Lam,et al.  Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. , 1994, Science.

[12]  J. Brownell,et al.  Fatty acid amides: scooting mode-based discovery of tight-binding competitive inhibitors of secreted phospholipases A2. , 1992, Journal of medicinal chemistry.

[13]  J. J. Rosa,et al.  Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. , 1993, Science.

[14]  K. H. Kalk,et al.  X-ray structure of phospholipase A2 complexed with a substrate-derived inhibitor , 1990, Nature.

[15]  D. Clawson,et al.  Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase A2 at 2.2 Å resolution , 1991, Nature.

[16]  N. Gensmantel,et al.  Discovery of new non-phospholipid inhibitors of the secretory phospholipases A2. , 1994, Journal of medicinal chemistry.

[17]  E. Dennis,et al.  Analysis of human synovial fluid phospholipase A2 on short chain phosphatidylcholine-mixed micelles: development of a spectrophotometric assay suitable for a microtiterplate reader. , 1992, Analytical biochemistry.

[18]  M. Gelb,et al.  Crystal structure of bee-venom phospholipase A2 in a complex with a transition-state analogue , 1990, Science.

[19]  W. Hendrickson,et al.  STEREOCHEMICALLY RESTRAINED CRYSTALLOGRAPHIC LEAST-SQUARES REFINEMENT OF MACROMOLECULE STRUCTURES , 1981 .

[20]  Characterization of the contractile effects of human recombinant nonpancreatic secretory phospholipase A2 (PLA2) and other PLA2s on guinea pig lung pleural strips. , 1993, The Journal of pharmacology and experimental therapeutics.

[21]  P. Warner,et al.  Non-peptidic inhibitors of human leukocyte elastase. 1. The design and synthesis of pyridone-containing inhibitors. , 1994, Journal of medicinal chemistry.

[22]  Á.,et al.  Diversity of Group Types , Regulation , and Function of Phospholipase & * , 2022 .

[23]  R C Wade,et al.  Rational modification of human synovial fluid phospholipase A2 inhibitors. , 1994, Journal of medicinal chemistry.

[24]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[25]  E. Dennis,et al.  Critical role of a hydrogen bond in the interaction of phospholipase A2 with transition-state and substrate analogues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Vadas,et al.  Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. , 1993, Circulatory shock.

[27]  T. A. Jones,et al.  A graphics model building and refinement system for macromolecules , 1978 .

[28]  J J Baldwin,et al.  Carbonic anhydrase inhibitors for the treatment of glaucoma , 2023, Медицинская этика.